KACM003

KACM003 is a preclinical-stage cell therapy candidate developed by Beijing Biohealthcare (Biohealthcare). It is based on the company's proprietary MTCA-CTL (Multi-Target Antigen-specific Cytotoxic T Lymphocytes) technology platform. This platform involves the induction and expansion of T lymphocytes that are specifically primed against multiple tumor-associated antigens (TAAs), aiming to address tumor heterogeneity and prevent immune escape. While the specific molecular targets for KACM003 have not been publicly disclosed, the MTCA-CTL approach generally involves the use of autologous immune cells to target a broad range of solid tumors or other conditions.